Mikhail Blagosklonny is an oncology professor who works at the cancer institute at Rosewell Park. He is a scientist studying cancer and aging. He attained an MD in internal medicine at the First Pavlov State Medical University located in St. Petersburg. He also attained a Ph.D. in Cardiology and experimental medicine from the University. In 2002, Mikhail was given the role of an associate professor of medicine in the medical college, located in New York. He then attended the Ordway research institute where he played the role of a senior scientist.
In 2009, Mikhail became a part of the Roswell Park Cancer Institute. He played the role of an Oncology professor. The skills and experience he attained in the various environments he worked allowed him to become an outstanding professor. Some of his areas of research include drugs for anti-aging, Biogerontology and cancer therapies which were targeted and safeguarded the cells which were healthy from damage. Read more on templeofthecave.com
Mikhail is the plays a role of One target’s and Cell cycle’s editor-in-chief. He also acts as the associate editor of therapy and biology, the International Journal of Cancer and the American Journal of Pathology. He is also on the editorial board of Cell Death and Differentiation. He has more than 200 research articles, reviews and book chapters which have been released in his name. Mikhail has developed a hypothesis concerning the role TOR signaling plays in aging and cancer. He recommended the utilization of Rapamycin. Rapamycin is a well-known medicine utilized in cancer
treatment. He authored the hyperfunction theory and additionally writes about chemotherapeutic engineering and cell cytotherapy. He believed that controlling aging and cancer can be controlled and cured with the aid of Rapamycin.
Mikhail Blagosklonny has been grouped among the most serious supporters of Rapamycin in the research of longevity. His research varies from molecular biology to cellular and clinical investigations. It majorly consists of ontogenesis, signal transduction, apoptosis, tumor suppressors, cell cycle and a host of others.
It was concluded in 2006 that Rapamune or Sirolimus which are recognized as rapamycin in basic science have already attained approval for use clinically and can be utilized instantly. Asides this, rapamycin can aid in the treatment of autoimmunity, cardiovascular diseases, metabolic disorders and all the diseases that are as a result of aging ranging from Alzheimer to osteoporosis. Basically, the most useful anti-aging drug which would be used in slowing down senescence and averting diseases will be rapamycin.
Many predictions as regards the TOR-centric model have undergone tests and have been proven to be true. As at 2010, there was only one prediction left, and that was the fact that rapamycin will be the major drug for anti-aging therapy.